07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

CARgenix, Sorrento deal

In August, Sorrento’s TNK Therapeutics Inc. subsidiary purchased CARgenix for $100 plus $6 million in TNK stock. TNK gains preclinical-stage CAR-modified T cell immunotherapy programs in solid tumors and HIV infection and the underlying CAR-T...